万春医药 BYSI 深 沪
等待开盘 05-19 09:30:00 美东时间
1.37
+0.010
+0.74%
华盛通- 最 高1.435
- 今 开1.30
- 成交量 1.89万股
- 最 低 1.30
- 昨 收 1.36
- 总市值 5.63万
- 52周最高 3.44
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 1.21
- 委 比 -69.49%
- 总股本 4.11万
- 历史最高 48.49
- 量 比 2.13
- 振 幅 9.93%
- 历史最低 0.542
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BeyondSpring GAAP EPS of -$0.06
BeyondSpring press release (BYSI): Q1 GAAP EPS of -$0.06. Cash, cash equivalents, and short-term investments were $7.9 million as of March 31, 2026 More on BeyondSpring Historical earnings data for Be...
05-13 19:29
BeyondSpring Q1 EPS $(0.05) Up From $(0.06) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
05-13 19:23
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported financial results for Q1 2026 and highlighted advancements in its pipeline. Plinabulin demonstrated potential as a backbone agent for ADC-based therapies, improving efficacy and tolerability. SEED's ST-01156, a molecular glue degrader, advanced into clinical development. The company's R&D expenses increased slightly, while G&A expenses decreased. Net loss was $2.4 million, and cash reserves were $7.9 million. BeyondSpri...
05-13 11:00
万春医药近一周股价波动较大 1家机构给出目标均价1.25美元
经济观察网 万春医药近期股价波动明显，已有机构给出相关目标价参考 股票近期走势： 近一周股价波动较大。4月30日收盘价为1.52美元，单日上涨3.40%。根据内...
05-03 00:47
万春医药（BYSI.US）4月27日收盘报1.56美元/股，跌8.5%
截至2026年4月27日（美国东部时间）收盘，万春医药(BYSI.US)报收于1.56美元/股，下跌8.5%，成交量1.84万股。
04-28 06:20
BeyondSpring publishes IO360 Summit presentation on plinabulin; PD-1/L1 resistance highlighted
BeyondSpring publishes IO360 Summit presentation on plinabulin; PD-1/L1 resistance highlighted BeyondSpring published a presentation titled “Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin.” The presentation was posted as part of the 2026 IO360 Summit materials. Document URL: h
03-26 21:37
BeyondSpring publishes corporate presentation; plinabulin clinical program advances and SEED targeted protein degradation pipeline grows
BeyondSpring publishes corporate presentation; plinabulin clinical program advances and SEED targeted protein degradation pipeline grows BeyondSpring outlined development plans for plinabulin, a small-molecule immune modulator positioned for use with docetaxel in later-line non-small cell lung cance
03-26 18:21
BeyondSpring GAAP EPS of -$0.21
BeyondSpring press release (BYSI): FY GAAP EPS of -$0.21. Cash, cash equivalents, and short-term investments: $12.6 million as of December 31, 2025. More on BeyondSpring Financial information for Beyo...
03-25 20:41
BeyondSpring Q4 EPS $(0.05)
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share.
03-25 20:35
BeyondSpring FY2025 operating loss narrows 2.25% to $8.7 million; R&D expenses jump 69.23% to $4.4 million
BeyondSpring FY2025 operating loss narrows 2.25% to $8.7 million; R&D expenses jump 69.23% to $4.4 million Net loss narrowed 2.25% to $8.7 million. R&D expenses jumped 69.23% to $4.4 million on higher drug manufacturing, NSCLC data management, Plinabulin combination research, regulatory consulting,
03-25 20:31
